Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis

Leukemia

Volumn 13, Issue 3, 1999, Pages 473-480

  Liu, P ^a   Oken, M ^b   Van Ness, B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Virginia Piper Cancer Institute   (United States)

Author keywords

Dexamethasone; IL 6; Interferon ; Myeloma

Indexed keywords

ALPHA INTERFERON; ANTIMITOTIC AGENT; DEXAMETHASONE; INTERLEUKIN 6; PROTEIN BCL X; STAT1 PROTEIN; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; CELL GROWTH; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0033045756     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401334     Document Type: Article

References (46)

1. Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao JA, Princier GL, Kung HF. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-clependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. J Clin Invest 1994; 94: 2317-2325.
2. Friedenberg WK, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171-175.
3. Avvisati G, Petrucci MT, Pulsoni A, Tribalto M, Lauta VM, Gernone A, Boccadoro M, Marmont F, Pileri A, Dammacco F et al. Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma. Eur J Haematol 1990; 52 (Suppl.): 9.
4. Anthes JC, Zhan Z, Gilchrest H, Egan RW, Siegel MI, Billah MM. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem J 1995; 309: 175-180.
5. Hardin J, Macleod S, Grigorieva I, Chang RX, Barlogie B, Xiao HQ, Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070.
6. Joshua DE, MacCallum J, Gibson J. Role of alpha interferon in multiple myeloma. Blood Rev 1997; 11: 191-207.
7. Jelinek DF, Aagaard TK, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99: 447-456.
8. Milner AE, Grand R, Gregory CD. Effects of interferon-alpha on human B cells - repression of apoptosis and prevention of cell growth are independent responses of Burkitt lymphoma lines. Intl J Cancer 1995; 61: 348-354.
9. Chaouchi N, Wallon C, Taieb J, Auffredou MT, Tertian G, Lemoine FM, Delfraissy JF, Vazquez A. Interferon-alpha-mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B cells role of Bcl-2 and c-Myc. Clinic Immunol Immunopathol 1994; 73: 197-204.
10. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates Bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994; 88: 268-274.
11. Cohen AM, Wacks T, Lurie BB, Levinsky H. Interferon-alpha and dexamethasone effect on AF10 myeloma cell line sialytransferase activity. Biochem Med Metabol Biol 1993; 50: 9-17.
12. Billadeau D, Liu PC, Jelinek D, Shah N, Lebien TW, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res 1947; 57: 2268-2275.
13. Schwartzman RA, Cidlowski JA. Glucocorticoid-induced apoptosis of lymphoid cells (review). Intl Arch Aller Immunol 1994; 105: 347-354.
14. Guizani L, Perrinwolff M, Breard J, Binetruy B, Bertoglio J. Mechanisms in interleukin-2 protection against glucocorticoid-induced apoptosis - regulation of AP-1 and glucocorticoid receptor transcriptional activities. J Inter Cytok Res 1996; 16: 601-609.
15. Yang YH, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990; 62: 1205-1215.
16. Helmberg A, Auphan N, Caelles C, Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 1995; 14: 402-460.
17. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B, Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 1995; 55: 3640-3646.
18. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-2011.
19. Kawano M, Kuramoto A, Hirano T, Kishimolo T. Cytokines as autocrine growth factors in malignancies (review). Cancer Surv 1989; 8: 905-919.
20. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162: 248-255.
21. l. Cancer Res 1995; 55: 2262-2265.
22. l and Bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 1995; 6: 647-653.
23. Fukada T, Hibi M, Yamanaka Y, Takahashi TM, Fujitani Y, Yamaguchi T, Nakajima K, Hirano T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5: 449-460.
24. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 1993; 53: 5320-5327.
25. Goldman LR, Salwen HR, Herst CV, Variakojis D, Bian ML, Le BM, Selvanayagan P, Marder R, Anderson R, Weitzman S et al. Characterization of a novel myeloma cell line, MM.I. J Lab Clin Med 1989; 113: 335-345.
26. McCloskey TW, Oyaizu N, Coronesi M, Pahwa S. Use of a flow cytometric assay to quantitate apoptosis in human lymphocytes. Clin Immunol Immunopathol 1994; 71: 14-18.
27. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1489.
28. l and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
29. Tong LQ, Werrbachperez K, Perezpolo JR. Retinoic acid induces apoptosis in PC12 cells independent of neurotrophic factors. J Neurochem 1997; 68: 1424-1435.
30. Schreiber M, Baumann B, Cotten M, Angel P, Wagner EF. Fos is an essential component of the mammalian UV response. EMBO J 1995; 14: 5338-5349.
31. Bromberg JF, Horvath CM, Wen ZL, Schreiber RD, Darnell JE. Transcriptionally active STAT1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 7675-7678.
32. Chin YE, Kitagavva M, Su W, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(Waf1/Cip1) mediated by Stal1. Science 1996; 272: 719-722.
33. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC. Interleukin-6 overcomes p21 Waf1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997; 90: 279-289.
34. Panayiotidis P, Ganeshaguru K, Jabbar S, Hoffbrand AV. Alpha-interferon (alpha-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro. Br J Haematol 1994; 86: 169-173.
35. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
36. Egle A, Villunger A, Koss M, Bock G, Gruber J, Auer B, Greil R. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha2. Eur J Immunol 1996; 26: 3119-3126.
37. Xu FH, Gardner A, Tu YP, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997; 97: 429-440.
38. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases (review). Philosophical Transactions of the Royal Society of London Series B: Biological Sciences. 1996; 351: 127-134.
39. Zhan QM, Fan SJ, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ. Induction of Bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9: 3743-3751.
40. L and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182: 821-828.
41. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997; 8: 343-352.
42. Chen CY, Faller DV. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J Biol Chem 1996; 271: 2376-2379.
43. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) (see comments). Cell 1996; 87: 619-628.
44. Westin J. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. Semin Oncol 1991; 27: 545.
45. Salmon SE, Crowley JJ. Alpha interferon plus alternate day prednisone improves remission duration in multiple myeloma compared to interferon alone. Proc Am Soc Clin Oncol 1997; 16: 13-17.
46. Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel RJ, O'Connell MJ. Complete remission induction with combined VBMCP chemotherapy and interferon (γIFN alpha 2b) in patients with multiple myeloma. Leuk Lymphoma 1996; 20: 447-452.